<DOC>
	<DOCNO>NCT02821533</DOCNO>
	<brief_summary>The aim current study study safety effectiveness TACE use high dose cisplatin treatment HCC . It hypothesize formulation safe improve therapeutic effect conventional TACE .</brief_summary>
	<brief_title>Chemoembolization Hepatocellular Carcinoma</brief_title>
	<detailed_description>Most patient HCC diagnose intermediate advanced stage tumor become unresectable , transcatheter arterial chemoembolisation ( TACE ) widely accept standard treatment international management protocol . The therapeutic effect TACE term objective tumor response variable modest ( 27 % -40 % ) , indicate actually much room improvement treatment . Internationally , high dos combination chemotherapeutic agent routinely widely use TACE major medical center . Locally , low dose cisplatin ( 10mg ) use chemotherapeutic agent TACE Hong Kong . There evidence show component chemotherapeutic agent TACE play significant role treatment effect TACE . In attempt improve treatment effect TACE , investigator propose formulation TACE use high dose cisplatin chemotherapeutic agent .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Patient factor 1 . Age &gt; 18 2 . ChildPugh A B cirrhosis 3 . ECOG performance status Grade 2 4 . No serious concurrent medical illness 5 . No prior treatment HCC except liver resection 6 . Creatinine clearance &gt; 55ml/min . Tumor factor 1 . HCC diagnose typical enhancement pattern cross sectional imaging histology . 2 . Unresectable locally advanced disease without extrahepatic disease 3 . Massive expansive tumor type measurable lesion CT 4 . Total tumor mass &lt; 50 % liver volume 5 . Largest tumor great dimension â‰¤ 15cm Patient factor 1 . Serum creatinine level &gt; 130 umol/L 2 . Presence biliary obstruction amenable percutaneous drainage 3 . ChildPugh C cirrhosis Evidence impair liver function 1 . History hepatic encephalopathy , 2 . Intractable ascites controllable medical therapy , 3 . History variceal bleeding within last 3 month , 4 . Serum total bilirubin level &gt; 40 umol/L , 5 . Serum albumin level &lt; 30g/L , 6 . INR &gt; 1.3 Tumor factor 1 . Presence extrahepatic metastasis 2 . Infiltrative lesion 3 . Diffuse lesion Vascular complication 1 . Hepatic artery thrombosis , 2 . Partial complete thrombosis main portal vein , 3 . Tumor invasion portal branch contralateral lobe , 4 . Hepatic vein tumor thrombus , 5 . Significant arterioportal shunt , 6 . Significant arteriovenous shunt</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>